Table 3.
Projected outcomes of six TB screening strategies for a cohort of 1000 healthcare workers over 20 years: alternate scenario with increased worker risk
| Strategy | Cost in 2015 $CAN | QALYs | New active TB cases | Deaths due to active TB | Deaths due to adverse event to treatment of active TB | Deaths due to adverse event to treatment of LTBI | True positive results | False positive results |
|---|---|---|---|---|---|---|---|---|
| Post-exposure screening only | ||||||||
| Tuberculin Skin Test | $198,480 | 15,234.05 | 8.90 | 0.39 | 0.0068 | 0.00109 | 195 | 17 |
| QuantiFERON®-TB-Gold | $228,809 | 15,233.75 | 8.73 | 0.38 | 0.0067 | 0.00119 | 201 | 30 |
| Targeted screening | ||||||||
| Tuberculin Skin Test | $257,670 | 15,232.84 | 8.18 | 0.36 | 0.0063 | 0.00152 | 193 | 96 |
| QuantiFERON®-TB-Gold | $365,397 | 15,231.90 | 8.23 | 0.36 | 0.0063 | 0.00177 | 184 | 146 |
| Annual screening | ||||||||
| Tuberculin Skin Test | $487,837 | 15,227.38 | 7.64 | 0.33 | 0.0058 | 0.00307 | 203 | 373 |
| QuantiFERON®-TB-Gold | $868,662 | 15,223.94 | 7.95 | 0.35 | 0.0061 | 0.00395 | 174 | 553 |
TB tuberculosis, QALYs quality-adjusted life years, LTBI latent tuberculosis infection